Chemomab Therapeutics Ltd CMMB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/13/24 EDT
0.814quote price arrow down-0.025 (-2.9797%)
Volume
40,098
52 week range
0.42 - 1.89
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.814
  • 52 Week High1.89
  • 52 Week High Date05/19/23
  • 52 Week Low0.42
  • 52 Week Low Date12/13/23

Key Stats

  • Market Cap11.574M
  • Shares Out14.22M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.40
  • YTD % Change59.61

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.814
  • 52 Week High1.89
  • 52 Week High Date05/19/23
  • 52 Week Low0.42
  • 52 Week Low Date12/13/23
  • Market Cap11.574M
  • Shares Out14.22M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.40
  • YTD % Change59.61

RATIOS/PROFITABILITY

  • EPS (TTM)-42.37
  • P/E (TTM)-0.02
  • Fwd P/E (NTM)-13.57
  • EBITDA (TTM)-25.392M
  • ROE (TTM)-91.02%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Chemomab Therapeutics Ltd

 

Profile

MORE
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention...
Nissim Darvish M.D. Ph.D.
Independent Chairman of the Board
Adi Mor Ph.D.
Chief Executive Officer, Director
Sigal Fattal CPA
Chief Financial Officer
Matthew Frankel
Chief Medical Officer, Vice President - Drug Development
Address
Kiryat Atidim, Building 7
Tel Aviv-yafo
6158002
Israel